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Small LDL size is common in patientswith type 2 diabetes and is associ-ated with an increased risk of car-
diovascular disease (1). LDL size is
determined by various constituents of
lipoprotein metabolism, such as lipo-
protein lipase (LPL) and hepatic lipase
(HL) activities, cholesteryl ester transfer
protein (CETP), as well as triglyceride
concentrations (2–4). Although abnor-
malities in LPL, HL, and CETP levels are
associated with a diabetic lipoprotein pro-
file, a relation to insulin resistance has
been found only with lipase activities
(5–7) but not with CETP (8,9). In this
cross-sectional study, we investigated the
relationship of LPL and HL activities and
CETP mass with LDL size in 426 subjects
with normal and impaired glucose metab-
olism or type 2 diabetes.
RESEARCH DESIGN AND
METHODS — The Hoorn Study is a
population-based cohort study of glucose
metabolism and cardiovascular risk fac-
tors among 2,484 inhabitants of the mu-
nicipality of Hoorn, which started in
1989. In 2000–2001, a follow-up was
conducted in selected subjects then aged
60 – 87 years, as previously described
(10). We invited all surviving subjects
with type 2 diabetes (n  176) and ran-
dom samples of individuals with normal
glucose metabolism (n  705) or
impaired glucose metabolism (n 
193) based on their glucose metabo-
lism status (World Health Organiza-
tion 1999 criteria) at the previous
examination in 1996–1998 (11). Of the
1,074 individuals invited, 648 (60.3%)
subjects participated. At the follow-up ex-
amination, a sample of 566 participated
in the postheparin test. The Ethical Re-
view Committee of the VU University
Medical Center approved the study. Writ-
ten informed consent was obtained from
all participants. LDL size was measured
by high-performance gel-filtration chro-
matography (12). CETP mass was deter-
mined using a two-antibody sandwich
immunoassay (13). LPL and HL activities
were measured in plasma collected 20
min after contralateral intravenous ad-
ministration of heparin, using an immu-
nochemical method (14). One hundred
and seven samples were excluded from
analyses because very low activities of LPL
and HL in postheparin plasma indicated
insufficient heparin delivery. Activities
were considered as very low if LPL activity
was 50 units/l and if HL activity was
72 units/l. The contribution of HDL
cholesterol, triglycerides, insulin, LPL,
HL, and CETP to LDL size was analyzed in
univariate and multivariate linear regres-
sion models in categories of glucose me-
tabolism, with LDL size as the dependent
variable with adjustment for sex.
RESULTS — Mean LDL size (in nano-
meters) was 21.6 0.4, 21.5 0.4, and
21.2  0.5 in subjects with normal, im-
paired glucose metabolism, and diabetes,
respectively. Mean LPL activity (in units
per liter) was 150  51, 147  51, and
135  42, respectively. There were no
differences in HL activity (mean 372 
135 units/l) and CETP mass (1.87 0.56
mg/l) between the three glucose metabo-
lism categories.
In this elderly population, we ob-
served a stronger positive association be-
tween LPL activity and LDL size in
subjects with impaired glucose metabo-
lism and type 2 diabetes than in subjects
with normal glucose metabolism, even af-
ter adjustment for triglyceride concentra-
tion, which was the most important
independent determinant of LDL size in
all glucose metabolism categories. A test
for interaction between LPL activity and
glucose metabolism was significant (P 
0.03), indicating that glucose metabolism
is an effect modifier in the relationship
between LPL activity and LDL size (Ta-
ble). Thus, higher LPL activity might pro-
tect against the development of small LDL
size, especially in subjects with type 2 di-
abetes, who have increased triglyceride
concentrations.
Mechanisms responsible for the pres-
ence of smaller LDL size in diabetic sub-
jects compared with nondiabetic subjects
are not fully understood. Lower LPL ac-
tivity contributes to an impaired removal
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of triglyceride-rich lipoproteins, whereas
an increased HL activity is associated with
a greater lipolysis of triglyceride-enriched
LDL. Several investigators have demon-
strated that individuals with type 2 diabe-
tes have increased triglyceride, reduced
HDL, and increased small dense LDL con-
centrations, all of which are thought to
have their origin in the insulin resistance
syndrome (15–17). Fasting insulin, com-
monly used as a measure of insulin resis-
tance, showed an inverse relation to LDL
size in a large population with various de-
grees of glucose metabolism (18), which
was confirmed in this study. Also, the
negative association of triglyceride con-
centration with LDL size was previously
reported in a population of 50 young
healthy subjects (9). Normally, insulin re-
duces hepatic apolipoprotein (apo)B se-
cretion by suppressing the delivery of
nonesterified fatty acids from adipose tis-
sue to the liver and by inhibiting new he-
patic cholesterol synthesis. Insulin also
enhances lipolysis and hepatic uptake of
triglyceride-rich apoB-containing li-
poproteins, including chylomicron rem-
nants, by the upregulation of LPL activity
and the stimulation of LDL receptor activ-
ity, respectively (19).
The amount of circulating triglycer-
ides is the single most important and in-
dependent factor affecting LDL size in the
present and other studies (5). Only in uni-
variate analysis, HL activity contributed
to LDL size in subjects with normal and
impaired glucose metabolism. However,
in the multivariate model containing
plasma triglyceride, LPL, and CETP, HL
activity did not contribute to LDL size in
any of the glucose metabolism groups.
This finding may indicate that in our pop-
ulation, HL activity is not rate limiting in
the formation of small dense LDL.
CONCLUSIONS — In conclusion,
we have demonstrated that high triglycer-
ide concentration and low LPL activity are
determinants of small LDL size, especially
in individuals with abnormal glucose me-
tabolism. These findings suggest that, be-
yond triglyceride concentration, activities
of lipolytic proteins explain the differ-
ences in LDL size in diabetic and nondia-
betic people.
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